Amolyt Pharma is a biotechnology company specializing in the development of peptide-based therapeutics for endocrine disorders and neurological diseases. The company leverages its expertise in peptide drug design, optimization, and delivery to address unmet medical needs in areas where traditional small molecule drugs and biologics have shown limitations.
The company's pipeline focuses on novel peptide therapeutics with an initial emphasis on endocrine disorders, particularly parathyroid disorders and osteoporosis, while expanding into neurodegenerative diseases including Alzheimer's disease. Amolyt's approach combines advanced peptide engineering with innovative delivery technologies to improve drug properties such as bioavailability, stability, and target engagement[1].
Headquarters: France (European operations)
Focus Areas:
Founded: Established with a mission to develop innovative peptide therapies for underserved patient populations
| Program | Target/Mechanism | Indication | Phase | Status |
|---|---|---|---|---|
| AMDX-2011P | Novel peptide therapeutic | Alzheimer's disease | Phase 2 | Recruiting |
| AZD-2373 | Peptide therapy | Parathyroid disorders | Preclinical | Research |
| Additional pipeline programs | Various peptide targets | Metabolic disorders | Discovery | Research |
AMDX-2011P represents Amolyt Pharma's expansion into neurodegenerative disease research. This novel peptide therapeutic is designed to address Alzheimer's disease through a mechanism distinct from approved amyloid-targeting antibodies.
Key Features:
Clinical Development:
The Phase 2 clinical trial (NCT06514001) is currently recruiting participants to evaluate the safety and efficacy of AMDX-2011P in patients with Alzheimer's disease:
Amolyt Pharma's core expertise lies in developing peptide therapeutics for endocrine disorders:
Parathyroid Disorders:
Metabolic Disorders:
Amolyt Pharma has developed proprietary capabilities in peptide drug development:
Peptide-based drugs offer several advantages over traditional small molecules and biologics:
| Property | Small Molecules | Biologics | Peptides |
|---|---|---|---|
| Target specificity | Low | High | High |
| Oral bioavailability | High | Low | Moderate |
| Brain penetration | Variable | Limited | Improved |
| Immunogenicity | Low | High | Low |
| Manufacturing cost | Low | High | Moderate |
Peptide therapeutics for Alzheimer's disease can operate through multiple mechanisms:
Beyond amyloid targeting, peptide approaches may provide direct neuroprotection through:
AMDX-2011P enters a competitive Alzheimer's disease therapeutic landscape:
| Drug | Company | Mechanism | Status |
|---|---|---|---|
| Lecanemab | Eisai/Biogen | Anti-Aβ protofibril | Approved |
| Donanemab | Eli Lilly | Anti-Aβ plaque | Approved |
| Semorinemab | Roche | Anti-tau antibody | Phase 3 |
| Tilavonemab | AbbVie | Anti-tau antibody | Phase 2 |
| AMDX-2011P | Amolyt Pharma | Novel peptide | Phase 2 |
AMDX-2011P Phase 2 Trial
Peptide Therapeutics
Amyloid Cascade Hypothesis
Amyloid-Beta)
Neuroscience Drug Development - Drug development